Results 241 to 250 of about 663,024 (297)
RETRACTED: Wang et al. Mipu1 Protects H9c2 Myogenic Cells from Hydrogen Peroxide-Induced Apoptosis through Inhibition of the Expression of the Death Receptor Fas. <i>Int. J. Mol. Sci.</i> 2014, <i>15</i>, 18206-18220. [PDF]
Wang G +6 more
europepmc +1 more source
Group Agency and Egalitarian Corporate Structure: The Epistemic, Incentive, and Control Dimensions
ABSTRACT What constitutes a good corporate agent? The article answers this question by critically applying List and Pettit's theory of group agency, which emphasizes three crucial dimensions of organizational design: epistemic quality, incentive compatibility, and control.
Chi Kwok, Chris Man‐Kong Li
wiley +1 more source
RETRACTION: ERK1/2-Dependent Inhibition of Glycolysis in Curcumin-Induced Cytotoxicity of Prostate Carcinoma Cells. [PDF]
International BR.
europepmc +1 more source
ABSTRACT Toxicological assessment is essential in NP approval for health and medical applications. Although 2D cell culture has been widely used, 3D models, especially spheroids, provide better predictive value for toxicological risk assessments since they replicate complex cellular interactions more accurately.
Bianca Montenegro +5 more
wiley +1 more source
Abstract Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight.
Patricia D. Maglalang +12 more
wiley +1 more source
With a little help from our friends: strong collaboration and networks for public health. [PDF]
Eurosurveillance editorial team.
europepmc +1 more source
Editorial: Current Issues in Governance, Economics and Finance: Toward Ecosystems
International Journal of Finance &Economics, EarlyView.
Fadi Alkaraan, Khaled Hussainey
wiley +1 more source
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol +5 more
wiley +1 more source

